Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.

about

Risk-stratifying capacity of PET/CT metabolic tumor volume in stage IIIA non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q38925887

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Risk-stratifying capacity of P ...... IA non-small cell lung cancer.

@en

type

Item

label

Risk-stratifying capacity of P ...... IA non-small cell lung cancer.

@en

prefLabel

Risk-stratifying capacity of P ...... IA non-small cell lung cancer.

@en

P1476

Risk-stratifying capacity of P ...... IA non-small cell lung cancer.

@en

P2093

Chenpeng Zhang

http://www.w3.org/2001/XMLSchema#string

Cindy Yuan

http://www.w3.org/2001/XMLSchema#string

Hai-Yan Liu

http://www.w3.org/2001/XMLSchema#string

Joshua H Finkle

http://www.w3.org/2001/XMLSchema#string

Mark K Ferguson

http://www.w3.org/2001/XMLSchema#string

Stephanie Y Jo

http://www.w3.org/2001/XMLSchema#string

Xuee Zhu

http://www.w3.org/2001/XMLSchema#string

Yonglin Pu

http://www.w3.org/2001/XMLSchema#string

P2860

Revisions in the International System for Staging Lung Cancer

Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging.

Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.

Metabolic Tumor Volume Measured by F-18 FDG PET/CT can Further Stratify the Prognosis of Patients with Stage IV Non-Small Cell Lung Cancer.

Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235.

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

Multidisciplinary management of lung cancer.

Cutpoint selection for discretizing a continuous covariate for generalized estimating equations.

Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times

P2888

s00259-017-3659-7

P304

1275-1284

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-017-3659-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28265739

http://www.w3.org/2001/XMLSchema#string

P932

6048959

http://www.w3.org/2001/XMLSchema#string